The Intracellular Activation of Lamivudine (3TC) and Determination of 2'-deoxycytidine-5'-triphosphate (dCTP) Pools in the Presence and Absence of Various Drugs in HepG2 Cells

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2001 Jan 3

PMID 11136299

Citations 9

Authors

S Kewn

P G Hoggard

S D Sales

M A Johnson

D J Back

Affiliations

Soon will be listed here.

Abstract

Aims: Lamivudine (3TC, 2'-deoxy-3'-thiacytidine) requires intracellular metabolism to its active 5'-triphosphate, 3TC-5'-triphosphate (3TCTP), to inhibit the replication of hepatitis B virus (HBV). We have investigated the activation of 3TC, in the presence and absence of a range of compounds, in HepG2 cells. The intracellular levels of the endogenous competitor of 3TCTP, 2'-deoxycytidine-5'-triphosphate (dCTP), were also determined and 3TCTP/dCTP ratios calculated.

Methods: The effects of a number of compounds on 3TC (3H; 1 microM) phosphorylation were investigated by radiometric h.p.l.c. dCTP levels were determined using a template primer extension assay. 3TCTP/dCTP ratios were calculated from these results.

Results: The phosphorylation of 3TC was significantly increased in the presence of either hydroxyurea (HU), methotrexate (MTX), or fludarabine (FLU). For example, at 100 microM HU, control 3TCTP levels were increased to 361% of control, whereas at 100 microM FLU, control 3TCTP levels were increased to 155%. dCTP pools were significantly reduced in the presence of HU and FLU, at 100 microM concentrations only. However, for all the above three compounds investigated, the ratio of 3TCTP/dCTP was favourably enhanced (e.g. at 1 microM MTX, 255% of control). Neither ganciclovir (GCV), lobucavir (LCV), penciclovir (PCV), adefovir dipivoxil (ADV), nor foscarnet (FOS) had any significant effects on 3TC phosphorylation or dCTP pools.

Conclusions: These results suggest that the activity of 3TC may be potentiated when combined with one of the modulators studied. The lack of an interaction between 3TC and the other anti-HBV agents is reassuring. These in vitro studies can be used as an initial screen to examine potential interactions at the phosphorylation level.

Citing Articles

Liver Damage During Treatment with Reverse-Transcriptase Inhibitors in HIV Patients.

Lungu G, Diaconescu G, Dumitrescu F, Docea O, Mitrut R, Giubelan L Curr Health Sci J. 2024; 50(2):181-197.

PMID: 39371070 PMC: 11447508. DOI: 10.12865/CHSJ.50.02.03.

CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target.

Friman T, Chernobrovkin A, Molina D, Arnold L SLAS Discov. 2020; 26(3):336-344.

PMID: 33208020 PMC: 7736708. DOI: 10.1177/2472555220973597.

Analysis of pharmacogenomic variants associated with population differentiation.

Yeon B, Ahn E, Kim K, Kim I, Oh J, Park T PLoS One. 2015; 10(3):e0119994.

PMID: 25807276 PMC: 4373713. DOI: 10.1371/journal.pone.0119994.

Induction of CYP26A1 by metabolites of retinoic acid: evidence that CYP26A1 is an important enzyme in the elimination of active retinoids.

Topletz A, Tripathy S, Foti R, Shimshoni J, Nelson W, Isoherranen N Mol Pharmacol. 2014; 87(3):430-41.

PMID: 25492813 PMC: 4352583. DOI: 10.1124/mol.114.096784.

Structural characterization of new deoxycytidine kinase inhibitors rationalizes the affinity-determining moieties of the molecules.

Nomme J, Murphy J, Su Y, Sansone N, Armijo A, Olson S Acta Crystallogr D Biol Crystallogr. 2014; 70(Pt 1):68-78.

PMID: 24419380 PMC: 3919262. DOI: 10.1107/S1399004713025030.

References

BURCHALL J . Comparative biochemistry of dihydrofolate reductase. Ann N Y Acad Sci. 1971; 186:143-52. DOI: 10.1111/j.1749-6632.1971.tb46965.x. View

Kewn S, Veal G, Hoggard P, Barry M, Back D . Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem Pharmacol. 1997; 54(5):589-95. DOI: 10.1016/s0006-2952(97)00189-5. View

Balis F, Savitch J, Bleyer W . Pharmacokinetics of oral methotrexate in children. Cancer Res. 1983; 43(5):2342-5. View

Mosmann T . Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2):55-63. DOI: 10.1016/0022-1759(83)90303-4. View

Sherman P, Fyfe J . Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. Anal Biochem. 1989; 180(2):222-6. DOI: 10.1016/0003-2697(89)90420-x. View

Suzuki S, Lee B, Luo W, Tovell D, Robins M, Tyrrell D . Inhibition of duck hepatitis B virus replication by purine 2',3'-dideoxynucleosides. Biochem Biophys Res Commun. 1988; 156(3):1144-51. DOI: 10.1016/s0006-291x(88)80752-6. View

Crumpacker C, Kowalsky P, Oliver S, Schnipper L, Field A . Resistance of herpes simplex virus to 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine: physical mapping of drug synergism within the viral DNA polymerase locus. Proc Natl Acad Sci U S A. 1984; 81(5):1556-60. PMC: 344876. DOI: 10.1073/pnas.81.5.1556. View

Freitas V, Matthews T . Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Antiviral Res. 1989; 12(4):205-12. DOI: 10.1016/0166-3542(89)90030-2. View

Hurta R, Wright J . Amplification of the genes for both components of ribonucleotide reductase in hydroxyurea resistant mammalian cells. Biochem Biophys Res Commun. 1990; 167(1):258-64. DOI: 10.1016/0006-291x(90)91759-l. View

10.

Manischewitz J, Quinnan Jr G, Lane H, Wittek A . Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro. Antimicrob Agents Chemother. 1990; 34(2):373-5. PMC: 171593. DOI: 10.1128/AAC.34.2.373. View

11.

Perrillo R, Schiff E, Davis G, Bodenheimer Jr H, Lindsay K, Payne J . A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med. 1990; 323(5):295-301. DOI: 10.1056/NEJM199008023230503. View

12.

Yokota T, Konno K, Chonan E, Mochizuki S, Kojima K, Shigeta S . Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro. Antimicrob Agents Chemother. 1990; 34(7):1326-30. PMC: 175975. DOI: 10.1128/AAC.34.7.1326. View

13.

Doong S, Tsai C, Schinazi R, Liotta D, Cheng Y . Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 1991; 88(19):8495-9. PMC: 52535. DOI: 10.1073/pnas.88.19.8495. View

14.

Kemena A, Fernandez M, Bauman J, Keating M, Plunkett W . A sensitive fluorescence assay for quantitation of fludarabine and metabolites in biological fluids. Clin Chim Acta. 1991; 200(2-3):95-106. DOI: 10.1016/0009-8981(91)90081-m. View

15.

Donehower R . An overview of the clinical experience with hydroxyurea. Semin Oncol. 1992; 19(3 Suppl 9):11-9. View

16.

Medina D, Hsiung G, Mellors J . Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro. Antimicrob Agents Chemother. 1992; 36(5):1127-30. PMC: 188848. DOI: 10.1128/AAC.36.5.1127. View

17.

Wang G, Seeger C . The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell. 1992; 71(4):663-70. DOI: 10.1016/0092-8674(92)90599-8. View

18.

Dieterich D, Poles M, Lew E, Mendez P, Murphy R, Addessi A . Concurrent use of ganciclovir and foscarnet to treat cytomegalovirus infection in AIDS patients. J Infect Dis. 1993; 167(5):1184-8. DOI: 10.1093/infdis/167.5.1184. View

19.

Pue M, Pratt S, Fairless A, Fowles S, Laroche J, Georgiou P . Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. J Antimicrob Chemother. 1994; 33(1):119-27. DOI: 10.1093/jac/33.1.119. View

20.

Pluda J, Cooley T, Montaner J, Shay L, Reinhalter N, Warthan S . A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1995; 171(6):1438-47. DOI: 10.1093/infdis/171.6.1438. View